Incyte Gains 15.3% in a Year: Is There Room for Further Growth?

Shares of Incyte (INCY) have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has outperformed the sector but lagged S&P 500 during this time frame.The outperformance can be attributed to new drug approvals and recent pipeline progress. Lead drug Jakafi (ruxolitinib) also maintains momentum.At the recently held J.P. Morgan Healthcare Conference, management highlighted that 2025 will be a transformational year for INCY with four potential launches.INCY Outperforms Indu ...